CDK4/6 Options and Supplement Considerations
Balanced look at palbociclib, ribociclib, and abemaciclib in HR-positive disease, including supplement considerations and monitoring questions
This page compares palbociclib, ribociclib, and abemaciclib in HR-positive, HER2-negative advanced breast cancer.
It focuses on the differences that usually matter most in practice.
That means fit with your biology, side-effect pattern, and monitoring burden.
It also looks at how curcumin, berberine, and EGCG may sit around CDK4/6 treatment when supplements are part of the plan.
This page is educational only.
It supports better questions and better shared decision-making.
It is not a substitute for oncology or pharmacist advice.
Jump to
Big picture
All three CDK4/6 inhibitors improve outcomes when added to endocrine therapy in HR-positive, HER2-negative advanced breast cancer.
That includes abemaciclib, ribociclib, and palbociclib.
The trial data and the real-world data do not tell exactly the same story.
That distinction matters.
Ribociclib and abemaciclib have the stronger phase 3 overall-survival narrative.
Palbociclib still remains a valid real-world option when its trade-offs fit better.
Palbociclib still matters in practice
Palbociclib improves progression-free survival, even though it has not shown the same clear randomised-trial overall-survival signal over endocrine therapy alone.
More recent comparative reviews and real-world series suggest the day-to-day gap between palbociclib and ribociclib is often smaller than the headline trial narrative implies.
Several retrospective and head-to-head analyses report no statistically significant difference in progression-free survival or overall survival between the two in routine practice.
The differences show up more consistently in side-effect pattern, monitoring burden, and treatment fit.
That means palbociclib remains a reasonable option when its trade-offs fit better with someone's biology, co-medications, or integrative plan.
This matters most when QT-interval risk is already front of mind.
It also matters when the plan may include QT-prolonging adjuncts such as hydroxychloroquine.
Ribociclib carries the clearer and more consistent QT-prolongation signal.
That can make palbociclib easier to justify in some real-life treatment plans.
The practical choice is often less about headline efficacy and more about fit.
That means fit with your counts, gut, liver, QTc, and tolerance for continuous versus cyclic dosing.
Recent reviews suggest ribociclib often acts as the practical default in fit patients.
Abemaciclib may fit better in selected endocrine-resistant or CNS-relevant settings.
Palbociclib may fit better when QT issues, co-medications, or an HCQ-based autophagy strategy matter more.
Key sources
Dosing patterns and daily life
Palbociclib dosing
Taken once daily for 21 days on and 7 days off
The week off often allows recovery of neutrophils
Practical downside: dose delays are common if counts stay slow to recover
Abemaciclib dosing
Taken continuously, twice daily, with no planned week off
Shorter half-life than ribociclib, which helps explain the BID schedule
Practical downside: if a side effect appears, it is often there every day
Ribociclib dosing
Taken once daily for 21 days on and 7 days off
The week off often allows recovery of neutrophils and liver enzymes
Some people also like the psychological break
Palbociclib and ribociclib feel more similar day to day.
Abemaciclib feels different because there is no planned break.
That difference matters more than it first seems.
A continuous drug can feel steadier.
A cyclic drug can feel more manageable.
That preference is personal.
“Taking Ibrance with letrozole at bedtime has helped me avoid midday energy slumps. It also reduces the risk of interactions with supplements I take during the day.”
— Group member, 2026
How to interpret interaction evidence
Cell and laboratory findings can identify a possible interaction. They do not confirm the same effect occurs in people.
Read interaction claims alongside human pharmacokinetic and clinical evidence. See Drug Interaction Evidence and CYP Enzymes for the evidence hierarchy and practical questions to ask.
Key sources
Side-effect profiles and QTc
A large trial and real-world literature now shows the toxicity patterns are not interchangeable.
That is often the real decision point.
Abemaciclib — more GI, less neutropenia
Higher rates of diarrhoea and broader GI side effects
Lower rates of high-grade neutropenia than ribociclib or palbociclib
Liver-enzyme rises still matter and need monitoring
Some analyses also suggest higher infection rates or treatment discontinuation in selected settings.
Ribociclib — more neutropenia, more QTc attention
Higher rates of grade 3 to 4 neutropenia
Scheduled ALT and AST monitoring is standard
QTc prolongation risk means ECG review matters from the start
That QTc issue becomes more important when other QT-prolonging drugs are already in the mix.
What is the QT interval?
Palbociclib — familiar workhorse, different trade-offs
Palbociclib has the longest real-world track record in this class.
Its main toxicity is neutropenia and related marrow suppression.
Liver, kidney, and QTc issues are usually less central than with ribociclib.
That makes it feel like a marrow-heavy but otherwise cleaner option in many clinics.
Key practical points
Multiple comparative studies report broadly similar real-world progression-free and overall survival versus ribociclib
Grade 3 to 4 neutropenia is common and often drives dose holds or reductions
The built-in week off often allows marrow recovery
Ribociclib, not palbociclib, carries the clearer formal QT-warning profile
Palbociclib can still justify baseline ECG and electrolyte review in selected patients.
It does not carry the same consistent QT signal as ribociclib.
Palbociclib, autophagy, and hydroxychloroquine
Preclinical work suggests palbociclib can induce protective autophagy in tumour cells.
That creates a plausible rationale for pairing it with hydroxychloroquine to block that escape route.
An early phase I trial tested palbociclib, letrozole, and hydroxychloroquine in HR-positive, HER2-negative metastatic breast cancer.
The combination looked feasible and showed on-target autophagy inhibition.
Higher-dose hydroxychloroquine also brought added toxicity.
That makes this an interesting but still specialist discussion, not a standard default approach.
In plain language, palbociclib may appeal when these issues matter most:
QT-interval risk is already a concern
other QT-prolonging drugs may need to stay in the plan
the team is comfortable managing neutropenia and prefers a longer real-world safety track record
Practical default choice
Multiple phase III trials show an overall-survival benefit for CDK4/6 inhibition plus endocrine therapy.
Ribociclib has especially strong survival data in endocrine-sensitive disease.
That is one reason many clinicians still reach for it first.
Key sources
Mechanistic nuances
All three drugs share a core mechanism.
They still differ in selectivity, off-target activity, and CNS behaviour.
Palbociclib
Inhibits CDK4 and CDK6 without the broader off-target profile seen with abemaciclib
Helps explain its strong marrow signal and more limited non-haematologic toxicity pattern
Has drawn special interest in autophagy discussions because tumour cells may use autophagy as a survival response to treatment
Abemaciclib
More potent against CDK4 than CDK6
Has measurable activity against other kinases, including CDK1, CDK2, CDK5, and CDK9
Shows more meaningful CNS penetration than the other two in preclinical and some clinical settings
That broader activity may help explain both its clinical strengths and its side-effect pattern.
Ribociclib
More selective for CDK4/6
Has less off-target kinase inhibition
Often behaves like the “cleaner” inhibitor, but with clearer neutropenia and QTc trade-offs
Key sources
SONIA trial and CDK4/6 timing
The SONIA phase 3 trial tested a practical sequencing question.
Does starting a CDK4/6 inhibitor in first line improve long-term outcomes more than saving it for second line?
For the overall study population, the answer was no.
First-line CDK4/6 use did not improve overall survival.
It also caused more grade 3 or higher toxicity which matters most when treatment burden, lab monitoring, ECG burden, cost, or quality of life are major concerns.
Note: a post hoc subgroup analysis showed women who were premenopausal when metastatic disease was diagnosed appeared to live longer with first-line CDK4/6 use.
CDK4/6 Postbiotics: Promising Real-World Results
When CDK4/6 inhibitors disrupt the gut, the consequences go far beyond discomfort.
Severe diarrhoea is not just a side effect — it directly impacts immune function, nutrient absorption, microbiome balance, and overall resilience.
Left unmanaged, this cascade can weaken the body's ability to tolerate treatment, forcing dose reductions or interruptions that compromise outcomes.
A clinical trial is now confirming what this framework has been pointing toward: the gut microbiome is not a passive bystander in CDK4/6 therapy.
It actively shapes both toxicity and treatment durability.
When the microbiome is supported correctly, drug tolerance improves, side effects decrease, and patients are more likely to stay on therapy at full dose.
The Breakthrough Insight
A 2024 study using a targeted postbiotic intervention alongside abemaciclib demonstrated a striking result: zero cases of Grade 3 diarrhoea in the first treatment cycle in the intervention group, compared to 7.9% under standard care.
Patients also experienced significantly fewer dose reductions.
This is not a marginal gain — it is a clinically meaningful shift in how treatment can be tolerated and sustained.
The Specific Postbiotic: PostbiotiX-Restore
The intervention used PostbiotiX-Restore, derived from Lactobacillus paracasei CNCM I-5220.
Importantly, this is not a probiotic.
It is a postbiotic — meaning the bacteria have been heat-inactivated, leaving behind fermented metabolites and structural components that interact directly with the gut environment.
It contains fermented Fructo-OligoSaccharides (FOS), produced using PBTech® technology.
The bacteria ferment the FOS for 24 hours and are then completely removed, resulting in a stable, bioactive metabolite fraction with no live organisms.
The protocol was simple and precise:
Start 7 days before abemaciclib
Continue through the full first cycle (day −7 to day +28)
1–2 sachets daily (2 g each), dissolved in water between meals
Why a Postbiotic — Not a Probiotic
This distinction is critical.
Over 81% of abemaciclib's active metabolites pass through the gut via faeces, creating a continuously hostile environment for live bacteria.
Probiotics struggle to survive under these conditions.
Postbiotics bypass this limitation entirely.
Because they contain no live organisms, they remain stable and active regardless of the drug environment.
They work by directly supporting gut barrier integrity, modulating inflammation, and influencing the microbiome ecosystem without needing to colonise.
This also makes them suitable for individuals with compromised immunity or sensitivities to live bacterial products.
Broader Implications
This same postbiotic strain has also demonstrated:
Restoration of gut barrier integrity (tight junction support)
Reduction in inflammation across gut and skin models
Protection against microbiome disruption in multiple contexts
These effects are highly relevant in cancer care, where epithelial barriers and immune signalling are constantly under pressure.
Real-World Feedback
One group member who implemented this approach reported:
"The postbiotix is working (in controlling my diarrhoea) so that is a huge win — thank you for that life saving research!"
Access and Availability
PostbiotiX-Restore is a commercially available product from Postbiotica S.r.l. in Italy.
It is not prescription-only and can be ordered internationally.
Typical cost ranges from €15–25 per box (20 sachets), making it relatively accessible compared to many supportive care interventions.
Direct source:
The Bigger Picture
The takeaway here is simple but powerful: maintaining microbiome integrity is not optional during CDK4/6 therapy — it is foundational.
This study provides proof of concept that targeted microbiome modulation can:
Reduce toxicity
Prevent dose reductions
Support treatment continuity
The framework is already validated.
The opportunity now is applying it consistently and earlier.
Study
Postbiotic supplementation reduces abemaciclib-induced diarrhea in HR+/HER2− metastatic breast cancer patients
PubMed:
Free full text on PMC:
Dealing with neutropenia on CDK4/6 drugs
This section is for people navigating neutropenia on palbociclib, ribociclib, or abemaciclib.
One of the hardest moments on a CDK4/6 inhibitor is hearing that counts are low and treatment may need to pause, reduce, or switch.
That fear is real.
Low counts can feel like lost ground.
This section helps separate the lab result from the larger treatment story.
Fever plus neutropenia is urgent.
If temperature reaches 38°C or higher, contact the treating team or go to emergency.
For the broader safety guide, see Neutropenia — Low White Blood Cell Count.
What is happening in the bone marrow
Your bone marrow makes white blood cells, red blood cells, and platelets.
CDK4/6 inhibitors slow cell division.
That is the point in the tumour.
It also affects early marrow cells.
CDK6 matters especially here.
When the drug hits marrow CDK6 strongly, white-cell production slows and neutrophils fall.
That is why neutropenia is so common with this drug class.
It is not proof the treatment has stopped working.
It is a predictable effect of the same pathway the drug is targeting.
What the blood test does not show well
A low neutrophil count in the bloodstream is still important.
It does not tell the whole immune story.
CDK4/6 inhibitors also seem to change how the tumour interacts with the immune system.
Reported effects include:
better tumour-antigen presentation
more supportive CD8+ T-cell activity and memory
less immune braking from some regulatory T-cell signals
changes in tumour-site neutrophils, macrophages, dendritic cells, and NK cells
That means two things can be true at once:
circulating white counts can be low
the drug can still be pushing the tumour environment in a more immune-visible direction
That does not cancel the infection risk.
It does help explain why the biology is more nuanced than “low count means treatment failure.”
Immune effects and why low counts are not the full story
The two main neutropenia patterns
Palbociclib and ribociclib
These drugs hit CDK4 and CDK6 more evenly.
That is one reason they hit bone marrow harder.
The practical pattern is:
more frequent grade 3 to 4 neutropenia
typical 21 days on, 7 days off schedule
the off-week often acts as a built-in marrow recovery window
Abemaciclib
Abemaciclib is much more weighted toward CDK4 than CDK6.
That is why marrow suppression is usually less severe.
The practical pattern is:
lower rate of severe neutropenia
continuous dosing with no planned rest week
GI toxicity, especially diarrhoea, becomes the bigger trade-off
In plain language, abemaciclib is not neutropenia-proof.
It is just usually gentler on marrow than palbociclib or ribociclib.
If the dose is reduced or treatment pauses
This is the part many people fear most.
Real-world data suggests that early dose reduction, especially in the first 12 weeks, is associated with worse outcomes.
That signal matters.
It should still be read carefully.
Association does not automatically prove the dose change caused the worse outcome.
People needing early reductions may already have had more fragile biology, more toxicity, or more aggressive disease.
Even so, the practical goal is clear:
stay on the most effective dose you can safely tolerate
avoid avoidable long breaks
recover counts as efficiently as possible
It is also important to remember this nuance:
a short planned break is already part of palbociclib and ribociclib design
later dose changes may matter less than very early ones
switching to abemaciclib can be a reasonable discussion when neutropenia keeps disrupting treatment
When standard support is not enough
Sometimes the main problem is not just the drug.
Sometimes the deeper issue is that the marrow does not have the nutrient support it needs to recover well.
That can happen even when blood tests look “normal enough.”
Genetic variants can affect transport, activation, or cellular uptake of key nutrients involved in marrow recovery.
The ones most worth checking in this context are:
folate — including MTHFR, SLC19A1, and DHFR
vitamin B12 — including TCN2, FUT2, and CUBN
vitamin D — including VDR, GC, CYP2R1, and CYP27B1
vitamin C — especially SLC23A1
zinc transport genes
The broader point is not “take more supplements.”
It is “check whether the form, delivery, or dose actually matches your biology.”
One discussion point for the off-week
This is a useful question to bring to the oncology team:
“One question to bring to your oncologist is whether it makes sense to ease off the stronger CDK6-inhibiting supplements during your ‘week off’ from treatment, and instead give your marrow a deliberate recovery window.”
That is not a universal rule.
It is a pattern worth noticing and discussing.
Key references
Supplements and Off Label Drug Interactions
Palbociclib interaction worksheet
This workbook is a structured resource for palbociclib interaction questions.
It covers supplements, integrative medicines, selected repurposed drugs, and protocol agents.
The image below is a preview of the intire 6 sheet Palbociclib Interactions workbook which you can open the online version via this link: workbook
What the workbook includes
A guide to interpreting in vitro and in vivo interaction evidence.
A detailed supplement and integrative-medicine interaction table.
A quick-risk summary and an off-label drug interaction section.
Curcumin with CDK4/6 inhibitors
Curcumin is one of the most plausible supplement overlaps in this setting.
It has broad pathway relevance and one direct preclinical CDK4/6-combination signal.
Preclinical synergy signal
A 2024 prostate-cancer study used LY2835219, the CDK4/6 inhibitor corresponding to abemaciclib
The combination with curcumin showed a synergistic inhibitory effect on proliferation and invasion
The combination also strengthened G1 arrest and RB-related signalling effects
This remains preclinical.
It does not prove the same effect in breast cancer patients.
It still makes curcumin one of the more interesting compounds in this specific decision.
Clinical implications and limits
No human trials yet define optimal dosing of curcumin with palbociclib, abemaciclib, or ribociclib in breast cancer
Curcumin can affect CYP enzymes and transporters in vitro
At supplement doses, the real-world interaction size is still not fully settled
Consider dose-timing separation 4+ hrs
The practical issue is usually not “does curcumin kill the benefit.”
It is usually “does this add enough liver or exposure uncertainty to change monitoring.”
Learn more about curcumin
For broader context, also see:
Key sources
Berberine, curcumin, and cell-cycle signalling
Berberine is interesting here for a different reason.
It sits closer to metabolic stress, PI3K/Akt/mTOR, and resistance biology.
Berberine plus curcumin
A 2019 study found that berberine plus solid-lipid curcumin caused more tumour-cell death than either alone
The combination reduced ATP and increased DNA fragmentation
It also more efficiently inhibited the PI3K/Akt/mTOR pathway
Why this matters for CDK4/6 therapy
The PI3K/Akt/mTOR axis cross-talks with the cyclin D–CDK4/6–RB pathway.
That creates a plausible additive logic.
Right now, it stays a mechanistic idea more than a clinical rule.
There is still no clear evidence that berberine antagonises CDK4/6 inhibitors.
The bigger question is still interaction burden.
Consider dose-timing separation 4+ hrs
That usually means CYP3A4, P-glycoprotein, GI tolerance, and liver handling.
Learn more about berberine
For broader context, also see:
Key sources
EGCG and CDK4/6 therapy
EGCG is a common part of integrative protocols.
Its main relevance here is not direct CDK4/6 synergy data.
It is pathway overlap and safety overlap.
Mechanistic overlap
EGCG can affect PI3K/Akt, MAPK, and NF-κB
It has repeated anti-proliferative and pro-apoptotic signals across tumour types
It also has mild antiplatelet effects that can matter in bigger supplement stacks
Specific points for CDK4/6 users
There is no evidence that EGCG clearly reduces palbociclib, abemaciclib, or ribociclib efficacy
The more realistic concern is additive toxicity or exposure effects through CYP and transporter pathways
Consider dose-timing separation 4+ hrs
Concentrated extracts also bring their own liver-risk question
That matters most with ribociclib and abemaciclib because both can already raise liver enzymes.
Learn more about EGCG
For broader context, also see:
Key sources
Galectin‑3, Cyclin D1, Modified Citrus Pectin(MCP) and CDK4/6: A Patient Guide
Galectin‑3 (Gal‑3) connects to the same cell-cycle pathway targeted by CDK4/6 inhibitors.
This includes palbociclib, ribociclib, and abemaciclib.
Modified citrus pectin (MCP) and pectin-rich foods may also influence Gal‑3 activity.
What is galectin‑3?
Galectin‑3 is a sugar‑binding protein found inside cells, on cell surfaces, and in blood. It helps cells stick, move, signal, and respond to injury—but in cancer, high Gal‑3 can support tumor growth, spread, inflammation and treatment resistance.
Key points:
Gal‑3 can act like an “upstream switch” that feeds pro‑growth signals into cancer cells.
Targeting Gal‑3 (by diet, supplements or drugs) is a way of gently pushing against some of these pro‑growth and pro‑metastatic signals.
How Gal‑3 links to cyclin D1 and CDK4/6
CDK4/6 inhibitors work by blocking the cyclin D–CDK4/6–Rb pathway, which controls whether cells move from the “resting” G1 phase into DNA‑copying (S phase). Gal‑3 can feed into this same pathway through cyclin D1.
In practical terms:
Cyclin D1 is a key “on switch” for CDK4/6.
Gal‑3 helps keep cyclin D1 levels up in several ways, so when Gal‑3 is high, CDK4/6 tends to be more active.
If Gal‑3 is reduced, cyclin D1 can fall, and CDK4/6 activity may be indirectly dialed down.
Why this matters in ER+ (Luminal) breast cancer
In ER+/HER2‑ (Luminal) breast cancers, many tumors rely on the cyclin D–CDK4/6–Rb axis for growth.
Cyclin D1 and CDK4 are often amplified or overexpressed in Luminal tumors.
Estrogen/ER signaling directly increases cyclin D1, and cyclin D1 can in turn support ER activity, creating a positive loop.
CDK4/6 inhibitors exploit this dependency by blocking Rb phosphorylation and holding cells in G1.
Because Gal‑3 can help maintain cyclin D1, it becomes a plausible upstream target in ER+ disease: lowering Gal‑3 might indirectly soften the same growth pathway CDK4/6 drugs target.
Where modified citrus pectin (MCP) fits in
MCP is a processed form of citrus pectin designed to be more absorbable and to bind Gal‑3’s carbohydrate‑recognition domain. It is the best‑studied “natural” Gal‑3 inhibitor so far.
What MCP has shown:
In animal models, MCP reduces tumor growth, tumor–endothelium adhesion and metastasis in several cancers.
Small human studies (e.g., prostate cancer, mixed solid tumors) suggest MCP can slow PSA doubling time and achieve disease stabilization in some patients.
MCP can lower circulating Gal‑3 in some non‑cancer contexts (fibrosis/inflammation studies), supporting its role as a Gal‑3 modulator.
Important limitations:
No trials yet show MCP improves survival or progression‑free survival in ER+ breast cancer or rescues resistance after CDK4/6 inhibitor failure.
Not all commercial MCP products are equal; their degree of modification and Gal‑3 binding can vary widely.
MCP is a promising, relatively low‑toxicity Gal‑3–modulating adjunct with some human data.
It does not replace CDK4/6 inhibitors.
Diet and whole‑food pectin (including whole lemons)
Beyond MCP, everyday foods can provide background levels of pectin and may gently influence Gal‑3 over time.
Pectin‑rich foods:
Citrus fruits (especially peel and pith, including lemons and oranges).
Apples (particularly with peel), some berries, carrots, okra, and other fruits/veg used for jam‑making (where pectin gels).
Freezing and grating whole lemons (including peel and pith) is one practical way to increase citrus pectin, flavonoids and vitamin C. This aligns with Gal‑3‑aware eating, but it is a supportive background habit, not a therapeutic‑dose substitute for MCP.
In a Nutshell
CDK4/6 inhibitors target a key growth pathway in ER-positive breast cancer.
Galectin‑3 can feed into that pathway by helping keep cyclin D1 active.
MCP and pectin-rich foods may offer complementary Gal‑3 support.
They do not replace CDK4/6 treatment.
Discuss any supplement plan with your oncology team.
Consider dose-timing separation 4+ hrs when unsure.
Matching drug choice to your biology and preferences
This is where the choice usually becomes clearer.
When palbociclib may fit better
Concern about QTc or a plan that may already include other QT-prolonging drugs
Preference for a long real-world track record and a more familiar toxicity pattern
Willingness to manage neutropenia and dose timing carefully
Interest in an autophagy-inhibition strategy that may include hydroxychloroquine
When abemaciclib may fit better
Baseline concern about severe neutropenia
Need to stay away from the stronger marrow-suppression pattern seen with palbociclib or ribociclib
Strong interest in the preclinical curcumin plus abemaciclib-type signal
Willingness to manage GI effects proactively
When ribociclib may fit better
Existing IBS, loose stools, or GI fragility
Comfort with 3 weeks on, 1 week off
Strong emphasis on the current overall-survival dataset in endocrine-sensitive disease
There is no perfect choice.
There is usually a better fit.
Key sources
Lab monitoring, supplements, and safety nets
Whichever CDK4/6 inhibitor you choose, monitoring matters more when several supplements are layered in.
That is especially true when they share liver handling, platelet effects, or transporter effects.
Monitoring priorities
CBC with differential — especially through the first 2 to 3 cycles
ALT, AST, bilirubin, and ALP — at baseline and regularly after
ECG and QTc — mandatory with ribociclib and still sensible at baseline if cardiac history exists
The exact emphasis changes by drug.
With palbociclib, the main watchpoint is usually blood counts.
With ribociclib, counts, liver enzymes, and QTc all matter early.
With abemaciclib, GI tolerance and liver monitoring often need the most attention.
Practical consult questions
Given my baseline labs and history, is there a strong reason to prefer palbociclib, ribociclib, or abemaciclib?
Can we match my neutrophils, liver enzymes, gut tolerance, and QTc to each drug’s risk pattern?
Here is my supplement stack. Which items worry you most, and why?
Can we use a monitoring plan rather than a blanket “stop everything” rule?
If one CDK4/6 inhibitor is poorly tolerated, are you open to switching to another within the class?
This is also where taking one supplement consideration seriously at a time helps.
That approach makes causality easier to track.
It also makes shared decision-making easier.
Key sources
Bottom line
All three CDK4/6 inhibitors are serious options.
If supplements are part of the real-life plan, the decision usually shifts.
Then the main issues become:
GI versus neutropenia burden
continuous versus cyclic dosing
QTc and liver monitoring
whether HCQ or other QT-prolonging drugs need to stay in the plan
how much uncertainty your team accepts around a supplement stack
Ribociclib often wins on broad default fit.
Abemaciclib can be the smarter choice when GI trade-offs are acceptable and marrow or CNS considerations matter more.
Palbociclib can be the smarter choice when QT concerns, co-medications, or an autophagy-focused integrative plan matter more.
The aim is not to remove every variable.
It is to understand which variable matters most first.
Related pages in this library
Before PI3K/AKT/mTOR Treatment: Trial Access After CDK4/6 — patient guide to treatment sequencing, trial access, and questions to ask before starting a PI3K, AKT, or mTOR inhibitor.
Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
Last updated
Was this helpful?